Skye Bioscience and Tautomer Bioscience Enter Exclusive Licensing Deal

[The commotion over mega-blockbuster drugs Ozempic and Wegovy has made tremendous headlines but this little-known biotech company may have a better answer for weight loss!]( While not the centerpiece of conversations, there is growing momentum in the endocannabinoid drug development frontier. Research suggests that the ECS may be a potential therapeutic target for numerous physiological conditions, including metabolic function and appetite regulation. With its leading effort to realize the pharmaceutical potential of endocannabinoid receptors, this underfollowed CB1 biotech company looks well-positioned for growth. With the potential of CB1 becoming clearer, now is a pivotal time to have the company on your radar! While CB1 receptors are generally expressed in the brain and other parts of the central nervous system, there is convincing evidence of disorders in which the ECS, specifically the CB1 receptor, is upregulated in peripheral tissues in a manner that exacerbates certain disorders, such as obesity and kidney disease. As a result, blocking or inhibiting the CB1 receptor has been shown to have beneficial therapeutic effects. The most famous example of this was with a drug called rimonabant. While Sanofi won clearance in Europe for rimonabant, it failed to gain support from the FDA’s outside advisors and was pulled from the European Union in 2009 over safety concerns. This innovative biotech company has developed a new generation of CB1-targeting drugs, designing them to avert the detrimental effects on the brain. Its innovative technology is a differentiated approach that could position CB1s to flourish the way they were meant to years ago! [Learn how the company’s Next-Genereation CB1-Inhibitor could be a promising solution to addressing obesity and create substantial revenue potential and shareholder value!]( --------------------------------------------------------------- This message is a PAID ADVERTISEMENT for Skye Bioscience, Inc. (OTCQB: SKYE) from Interactive Offers. StockEarnings, Inc receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $1,900. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either Skye Bioscience, Inc. (OTCQB: SKYE) or Interactive Offers. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding Skye Bioscience, Inc. (OTCQB: SKYE) on Smallcaps Daily website for additional information about the relationship between Interactive Offers and Skye Bioscience, Inc. (OTCQB: SKYE). Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click [Unsubscribe](. StockEarnings, Inc 33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA W: 877.6.STOCKS StockEarnings.com